Adaptive Biotechnologies

Adaptive BiotechnologiesAdaptive Biotechnologies
Adaptive Biotechnologies

Adaptive Biotechnologies

Leveraging the adaptive immune system to diagnose and treat disease.

Website
2009ActiveSeattle, United States
Rate
Advertise here

About

Adaptive Biotechnologies harnesses the adaptive immune system to power the Age of Immune Medicine, translating immune system genetics into actionable data. Their core offerings include clonoSEQ for Measurable Residual Disease assessment and an Immune Medicine Platform that informs clinical trials and the development of transformative medicines. They serve clinicians, biopharma companies, and patients by transforming how diseases are detected, monitored, and treated.

Technology stack

detected 2026-07-12
Email
gateway-fronted
Hosting
self_managed
Stack
Analytics
SEO
Compliance
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies harnesses the adaptive immune system to power the Age of Immune Medicine, translating immune system genetics into actionable data. Their core offerings include clonoSEQ for Measurable Residual Disease assessment and an Immune Medicine Platform that informs clinical trials and the development of transformative medicines. They serve clinicians, biopharma companies, and patients by transforming how diseases are detected, monitored, and treated.

How much funding has Adaptive Biotechnologies raised?

Adaptive Biotechnologies has raised a total of $300M in funding. The most recent round on record is Series D.

Where is Adaptive Biotechnologies headquartered?

Adaptive Biotechnologies is headquartered in Seattle, United States.

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

What industry does Adaptive Biotechnologies operate in?

Adaptive Biotechnologies operates in Biotech, HealthTech, Genomics, Drug Discovery, Clinical Trials, Diagnostics.

What is Adaptive Biotechnologies's revenue?

StartupHub estimates Adaptive Biotechnologies's annual revenue at $13.7M (range $6.7M to $130.3M, 28% confidence), based on comparable companies in the sector.

What is Adaptive Biotechnologies's valuation?

StartupHub estimates Adaptive Biotechnologies's effective valuation at $1.3B (range $750.0M to $1.8B, 10% confidence), based on comparable companies in the sector.